Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT

Summit Creek Advisors LLC acquired a new stake in Artivion, Inc. (NYSE:AORT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 120,354 shares of the company’s stock, valued at approximately $2,704,000. Summit Creek Advisors LLC owned approximately 0.25% of Artivion as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth about $27,000. Rockefeller Capital Management L.P. increased its holdings in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the period. Finally, KBC Group NV bought a new position in shares of Artivion during the 4th quarter valued at about $65,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Finally, Citigroup restated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Artivion Stock Up 1.6%

Shares of Artivion stock opened at $28.78 on Wednesday. The business’s 50 day simple moving average is $24.60 and its 200 day simple moving average is $30.33. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The firm has a market cap of $1.40 billion, a PE ratio of -411.08 and a beta of 1.24. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, analysts predict that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.